Colleges and universities tend to be one of the best scholarship resources for international undergraduate students. Experts ...

Community Supported Shelters, which first opened its doors in Lane County in 2013, is opening a brand-new center ...

Cytokinetics, Incorporated ( CYTK ), a biopharmaceutical company focused on developing muscle-directed therapies, announced positive results from its pivotal Phase 3 ACACIA-HCM trial of aficamten in ...

Their new three-year term will take effect from September 1, 2026, according to the Gazette Notice issued by the Cabinet ...

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with ...

Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with ...

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both ...

Key takeawaysThere are currently no approved treatments for symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The ACACIA-HCM trial ...

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Meto ...

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...